Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03191058 · ClinicalTrials.gov registry record · NA
Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression
A NA study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 239
- Enrollment target
NCT03191058: Completed NA study, sponsored by University of Texas Southwestern Medical Center.
NCT03191058 is a NA study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 239 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03191058, a NA study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 239 participants
- Enrollment target
Study Summary
This trial aims to assess the efficacy and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for depression. Even with multiple medication trials, 30 - 40% of patients will experience a pharmacologically resistant form of illness. The ineffectiveness of current treatments for major depressive disorder (MDD) coupled with the economic burden associated with the disorder engenders a need for novel therapeutic interventions that can provide greater response and remission rates.
Primary Outcome
This scale is used to quantify the severity of symptoms of depression * Scale range: 0-76 (total score) * Lower scores indicate lower severity of depressive symptoms (i.e., better outcome) * Higher scores indicate higher severity of depressive symptoms (i.e., worse outcome) Remission defined as a HRSD-24 total score of ≤10 and 60% reduction from baseline on two consecutive assessments. The outcome is reported as number of participants meeting remission criteria in each treatment group.
Interventions
- DEVICE Electroconvulsive Therapy
- DEVICE Magnetic Seizure Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2018-06-26 |
| Est. Completion | 2024-11-22 |
| Phase | NA |
What the finished NCT03191058 record still lists
NCT03191058 is an interventional study that assigns participants to a tested intervention. The registered 239 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Electroconvulsive Therapy is the first listed.
NCT03191058 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03191058 about?
NCT03191058 is a clinical study titled "Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression". This trial aims to assess the efficacy and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for depression. Even with multiple medication trials, 30 - 40% of patients will experience a pharmacologically resistant form of illness. The ineffectiveness...
What is the current status of trial NCT03191058?
This trial is currently completed. It is a NA study. The enrollment target is 239 participants. The study started on 2018-06-26. Estimated completion is 2024-11-22.
What interventions are being tested in trial NCT03191058?
The interventions under investigation include: Electroconvulsive Therapy (DEVICE), Magnetic Seizure Therapy (DEVICE).
Who is sponsoring clinical trial NCT03191058?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03191058's enrollment target sits among peer trials
239 459th of 2000 higher than 1,542 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI